- Vertex to buy Crinetics for $85/share (~$10B), ~100% premium. Deal funds: cash and debt. Includes marketed PALSONIFY and Phase 3 atumelnant. Close expected Q3 2026 pending approvals.
- RBC Capital kept Vertex Pharmaceuticals (VRTX) at Outperform and raised its price target to $570 from $543, lifting the firm's valuation for VRTX.
- Vertex (VRTX) will report Q2 2026 results after market close Monday, Aug 3, 2026, and hold a conference call and webcast at 4:30 p.m. ET; dial-in details provided.
TradingView
Key facts: Vertex to Buy Crinetics for $10B at $85; RBC Raises Target; Q2 Results Aug 3
- Sources
- TradingView
- Markets
- Stocks
- Active symbols
- NASDAQ:VRTX
- Language
- English
Vertex to buy Crinetics for $85/share (~$10B), ~100% premium. Deal funds: cash and debt. Includes marketed PALSONIFY and Phase 3 atumelnant. Close expected Q3 2026 pending approval